Search clinical trials for: AZD4547

Total 51 results

National Cancer Institute (NCI)

Completed

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
AstraZeneca

Completed

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

Cancer | Advanced Solid Malignancies

Japan
AstraZeneca

Terminated

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Cancer | Advanced Solid Malignancies

United States, Italy, United Kingdom, France, Germany, Spain, Netherlands
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Urothelial Carcinoma

China
Abbisko Therapeutics Co, Ltd

Completed

ABSK091 Food Effect Study in Healthy Subjects

Health, Subjective | Food-drug Interaction

Taiwan
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene Amplification

United States, Canada
AstraZeneca

Completed

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

Relapsed/Refractory Peripheral T-cell Lymphoma | Relapsed/Refractory Classical Hodgkins Lymphoma

Italy, Sweden, United States, Taiwan, Korea, Republic of, United Kingdom, Australia, France, Singapore
AstraZeneca

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | High Risk Myelodysplastic Syndrome | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma | Richter's Syndrome | T-cell Non-Hodgkin Lymphoma | Relapsed or Refractory...

United Kingdom, Germany, Netherlands
AstraZeneca

Completed

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

Carcinoma | Cancer | Tumors

Japan
AstraZeneca

Terminated

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Lymphoma

United States, Canada
AstraZeneca

Terminated

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States, Canada
AstraZeneca

Terminated

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Lymphoma | Non-Hodgkin Lymphoma | NHL

United States
AstraZeneca

Completed

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

Neoplasms

United States
AstraZeneca
National Institutes of Health (NIH); Eolas Therapeutics INC.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers

Smoking Cessation

United States
AstraZeneca

Completed

Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

Obesity

Sweden
AstraZeneca

Completed

Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses (MAD)

Diabetes Mellitus Type 2

Sweden
AstraZeneca

Completed

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017

Healthy

Sweden
AstraZeneca

Completed

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD5847 After Multiple Doses Over 14 Days

Healthy

United States
AstraZeneca

Completed

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.

Healthy

Japan
AstraZeneca

Completed

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451 (AZD4451 SAD)

Bipolar Disorder

United States
AstraZeneca
Parexel

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

Healthy Participants

United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.

Rheumatoid Arthritis

Germany, United Kingdom
AstraZeneca

Completed

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Bladder Cancer | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer | Transitional Cell Bladder Cancer

United States, Spain, United Kingdom, Germany, Canada
AstraZeneca
Altasciences Company Inc.

Completed

A Safety Study of AZD4041 in Healthy Participants

Opioid Use Disorder (OUD)

Canada
University of Birmingham

Completed

Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. (IIH:DT)

Idiopathic Intracranial Hypertension

United Kingdom
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Urothelial Carcinoma

China
AstraZeneca

Terminated

Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer (SHINE)

Gastric Cancer | Gastro-oesophageal Junction Cancer

Bulgaria, Czech Republic, Italy, Korea, Republic of, Spain, United Kingdom, Hungary, Romania, Ukraine, Belgium, Canada, Germany, Taiwan, India, Japan, France
University of Leeds

Completed

Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) (GC-SHealD)

Diabetes Mellitus, Type 2

United Kingdom
AstraZeneca
Quintiles, Inc.

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers

Healthy

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer | Squamous Cell Lung Cancer

United States
AstraZeneca

Active, not recruiting

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY)

Muscle Invasive Bladder Cancer

Spain, United States, Canada, France, United Kingdom
Assistance Publique - Hôpitaux de Paris

Completed

Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion" (TARGET)

Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion | Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion

France
Imperial College London
AstraZeneca; Cancer Research UK

Completed

AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL) (RADICAL)

Breast Cancer

United Kingdom
AstraZeneca

Completed

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

Raised Intraocular Pressure

Sweden, United States, United Kingdom
AstraZeneca

Completed

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients (GLOW)

FGFR Inhibition, Pharmacokinetics, Biomarkers | ER+ Breast Cancer

Czech Republic, Italy, United Kingdom, Hungary, Germany, Romania, Belgium, France
University of Birmingham
Pfizer; AstraZeneca; Mirati Therapeutics Inc.; Cancer Research UK; Experimental Cancer...

Active, not recruiting

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Adenocarcinoma | Carcinoma, Squamous Cell | Non-Small Cell Lung Cancer

United Kingdom
AstraZeneca
Daiichi Sankyo Co., Ltd.

Active, not recruiting

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens (DG-06)

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Milton S. Hershey Medical Center

Terminated

Angiotensin-(1-7) in Peripheral Arterial Disease

Peripheral Arterial Disease

United States
AstraZeneca
Parexel

Active, not recruiting

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

Advanced Haematological Malignancies

Spain, United States, Canada, Korea, Republic of, Poland, Australia, France, United Kingdom, Ireland
UNICANCER
AstraZeneca; Intergroupe Francophone de Cancerologie Thoracique; Fondation ARC

Completed

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (SAFIR02_Lung)

Non-small Cell Lung Cancer Metastatic

France
AstraZeneca

Completed

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

Opioid Use Disorder

United States
AstraZeneca

Completed

Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Sweden, Netherlands
AstraZeneca
Parexel

Completed

Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
AstraZeneca

Withdrawn

Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis (Du Lac)

Venous Thrombosis | Pulmonary Embolism
AstraZeneca

Completed

A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.

Rheumatoid Arthritis | Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Tolerability | Safety

Germany
AstraZeneca

Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)

Advanced Solid Malignancies

United States, Korea, Republic of, Spain, Australia, Sweden, Germany, United Kingdom
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
University of Oxford
AstraZeneca

Completed

Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)

Iatrogenic Cushing's Disease

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Phase 2a EBA Trial of AZD5847

Tuberculosis

South Africa
UNICANCER
AstraZeneca; Fondation ARC

Active, not recruiting

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (SAFIR02_Breast)

Metastatic Breast Cancer

France

Search clinical trials for: AZD4547

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations